Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors

Summary

This is a multicenter, open-label, dose escalation study of MNK-010 in subjects with advanced solid malignancies who have failed conventional therapy. The safety, tolerability, pharmacokinetic (PK) profile, and preliminary antitumor activity of ascending doses of MNK-010 will be evaluated in subjects with advanced solid tumors.

Timeline

Start

2013-07

Primary completion

2016-05

Completion

2016-07

Publications

• Paira S, Borden KLB. Multipurpose RNA maturation factors dysregulate multiple mRNA processing steps simultaneously and provide new therapeutic opportunities. RNA Biol. 2025 Dec;22(1):1-14. doi: 10.1080/15476286.2025.2503040. Epub 2025 Jun 9.

Drugs

Indications